A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

Item

http://www.wikidata.org/entity/Q51187404

Q51187404

about

Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections Nonspecific effect of Mycograb on amphotericin B MIC Optimizing Outcomes in Immunocompromised Hosts: Understanding the Role of Immunotherapy in Invasive Fungal Diseases Emerging drugs and vaccines for candidemia Progress toward a Staphylococcus aureus vaccine Human monoclonal antibody-based therapy in the treatment of invasive candidiasis Development of a vaccine against Staphylococcus aureus Monoclonal antibody-based therapies for microbial diseases Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans Reverse genetics in Candida albicans predicts ARF cycling is essential for drug resistance and virulence Serological profiling of a Candida albicans protein microarray reveals permanent host-pathogen interplay and stage-specific responses during candidemia Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin Hsp90 orchestrates stress response signaling governing fungal drug resistance Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence The stress responsive and morphologically regulated hsp90 gene from Paracoccidioides brasiliensis is essential to cell viability Progress towards recombinant anti-infective antibodies.Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism.Pathogen-specific antibodies: codependent no longer Clinical factors associated with a Candida albicans Germ Tube Antibody positive test in Intensive Care Unit patients Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco.Regulatory circuitry governing fungal development, drug resistance, and disease.Vaccines against Coccidioides Prediction of the clinical outcome in invasive candidiasis patients based on molecular fingerprints of five anti-Candida antibodies in serum Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis Fungicidal monoclonal antibody C7 interferes with iron acquisition in Candida albicans Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis Novel strategies to fight Candida species infection.Blocking Hsp70 enhances the efficiency of amphotericin B treatment against resistant Aspergillus terreus strains.Combination Antifungal Therapy: A Review of Current Data.Influence of IgG Subclass on Human Antimannan Antibody-Mediated Resistance to Hematogenously Disseminated Candidiasis in Mice.Invasive fungal infections in acute leukemia.Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients.Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies.In search of the holy grail of antifungal therapy Immunomodulatory therapy in yeast infections.Combination antifungal therapy: the new frontier.Interactions of the fungal pathogen Candida albicans with the host.

P2860

Q24239978-B4277A57-D2F0-43A0-9D14-5DF1B275E4D8 Q24243629-2CD7EDF6-5C0D-40CF-8EB1-166144CB9B55 Q24632922-91D88904-5DF0-4E0A-AC6C-DB8297D49D4D Q26774692-FB2991C8-7727-4A50-867C-153D2811B07E Q26828993-A975299F-C018-439B-9C39-5198359B40C9 Q26829702-78CC6DF0-D021-4CDB-9FCB-BF0CE53DCF94 Q26864291-F838A83E-5326-4E97-9BE3-8ABA4CEFB07F Q27015365-1CE7FECE-A12F-49E5-A844-FF48B80F10C9 Q27490830-E838390F-7675-4AA8-B47A-C3DC2BC86AD2 Q28082407-B71627B7-6AC6-4EB9-8012-2E7FB3C1C1D7 Q28472787-AD64D734-10BE-4442-BF88-8E0C96B95C08 Q28473465-CFEC79B6-8A74-46FE-BD64-F84100C74C21 Q28475818-046EB8BC-6EA5-4F13-ABD0-AE7BB42F0830 Q28475988-305A412F-D88F-4890-BD04-6FFEE1F21891 Q30862390-E2CDB54C-65C5-4C4F-ABF2-755B38DBAC1A Q33371122-526F268C-F315-435C-AD6C-DA7F451D5D39 Q33568256-0972557F-C41D-4C8E-9301-31D225CB8EA6 Q33755308-D1D4A400-03E2-4A6B-BBC1-2AB6D7AA8255 Q33755471-A719EFF8-10F3-47D8-B5C3-D0E7844706E8 Q33841485-309507C5-79A2-442D-BCE5-E9A35DA996BE Q33876645-C0B0C044-9240-4361-88A3-3D02A7F8CE8B Q33957908-56D504A0-EBD0-4814-9AA3-9F82157368C2 Q34190284-37BBA1D3-AC8F-4F2D-8C29-5BB6368C5923 Q34358234-8745EE9E-F75C-4863-9F65-20E57657CE42 Q34454950-97B447A6-7B9B-4D83-804B-8A3BCC1134B4 Q35065740-654EFBD7-A11C-4167-B526-C9E46D99D2BA Q35065782-6A1DAF06-207F-46AC-99BD-9E7F97AD9B0D Q35214605-64A0FA1C-B3A3-4E48-B1BB-5E6F377F87B6 Q35271053-3D90B42A-D711-415D-AFAE-70BAEDAB9C8C Q35406737-EB2BB4BB-6E43-40B1-9B88-12F55DBB0A80 Q35746085-8C2FEBC6-2753-4E74-8FB9-C647A6D872A7 Q36369805-EB5F242E-B37B-4587-BFEC-188AED7842FF Q36513475-C92E728F-CDD3-4AB1-80D2-9067A688C57F Q36612597-4A3FF20F-F396-400D-B094-833191494006 Q36613885-90D6374B-2F1C-4A9D-A22B-F5AC70254666 Q36670916-D2D2BB65-BE33-4002-A870-492F4161F521 Q36672181-8315AFD2-1ED6-4C2F-B1E4-A070CC295ACB Q36723814-DC194820-34C8-4092-83D8-6E340AB5AC16 Q36895652-846CA274-1A34-43E7-8D17-5BA2D25BBB6D Q36895656-A245C4F1-88FF-44FC-A4D3-0F291F8F143E

P2860

A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

Item

http://www.wikidata.org/entity/Q51187404

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

A randomized, blinded, multice ...... nts with invasive candidiasis.

@en

A randomized, blinded, multice ...... nts with invasive candidiasis.

@nl

type

Item

label

A randomized, blinded, multice ...... nts with invasive candidiasis.

@en

A randomized, blinded, multice ...... nts with invasive candidiasis.

@nl

prefLabel

A randomized, blinded, multice ...... nts with invasive candidiasis.

@en

A randomized, blinded, multice ...... nts with invasive candidiasis.

@nl

P1476

A randomized, blinded, multice ...... ents with invasive candidiasis

@en

P2093

Frédérique Jacobs

http://www.w3.org/2001/XMLSchema#string

Gary Masterson

http://www.w3.org/2001/XMLSchema#string

James Burnie

http://www.w3.org/2001/XMLSchema#string

Jan Pachl

http://www.w3.org/2001/XMLSchema#string

Jorge Garbino

http://www.w3.org/2001/XMLSchema#string

Jukka Takala

http://www.w3.org/2001/XMLSchema#string

Koenraad Vandewoude

http://www.w3.org/2001/XMLSchema#string

Lubos Drgona

http://www.w3.org/2001/XMLSchema#string

Mickael Aoun

http://www.w3.org/2001/XMLSchema#string

Mycograb Invasive Candidiasis Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance.

Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003.

Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII.

Guidelines for the management of intravascular catheter-related infections.

Cell biology. A fungal Achilles' heel.

Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi.

Assembly and activation of the plasma kallikrein/kinin system: a new interpretation.

Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90

P304

1404-1413

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/503428

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Manu Lng Malbrain

Ben van der Hoven

P577

2006-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7161384

http://www.w3.org/2001/XMLSchema#string

P698

16619152

http://www.w3.org/2001/XMLSchema#string

P921

antibody

A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

about

P2860

P2860

A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921